Issue 6, 2025

Artificial intelligence approaches for anti-addiction drug discovery

Abstract

Drug addiction remains a complex global public health challenge, with traditional anti-addiction drug discovery hindered by limited efficacy and slow progress in targeting intricate neurochemical systems. Advanced algorithms within artificial intelligence (AI) present a transformative solution that boosts both speed and precision in therapeutic development. This review examines how artificial intelligence serves as a crucial element in developing anti-addiction medications by targeting the opioid system along with dopaminergic and GABAergic systems, which are essential in addiction pathology. It identifies upcoming trends promising in studying less-researched addiction-linked systems through innovative general-purpose drug discovery techniques. AI holds the potential to transform anti-addiction research by breaking down conventional limitations, which will enable the development of superior treatment methods.

Graphical abstract: Artificial intelligence approaches for anti-addiction drug discovery

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Review Article
Submitted
23 Jan 2025
Accepted
07 May 2025
First published
13 May 2025
This article is Open Access
Creative Commons BY license

Digital Discovery, 2025,4, 1404-1416

Artificial intelligence approaches for anti-addiction drug discovery

D. Chen, J. Jiang, N. Hayes, Z. Su and G. Wei, Digital Discovery, 2025, 4, 1404 DOI: 10.1039/D5DD00032G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements